CareLit · DOI-Nachweis · Pneumologie
CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
DOI 10.1055/s-0039-1678250
Bibliografische Angaben
Nachweis in CareLit
Autor:innenD Christoph, S Gettinger, JT Beck, X Yang, B Telivala, D Morgensztern, V Velcheti, S Ramalingam, K Schalper, M Dajee, A Ranck, R Yang, DR Spigel
ZeitschriftPneumologie
AusgabeS 01 S 01/2019
Jahrgang / SeitenJg. 73
Kernaussage aus der Literatur
Abstract-Vorschau
CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC
Zitieren
Zitierempfehlung
D Christoph, S Gettinger, JT Beck, X Yang, B Telivala, D Morgensztern, V Velcheti, S Ramalingam, K Schalper, M Dajee, A Ranck, R Yang, DR Spigel (2019) CheckMate 592: a phase 2 exploratory study of biomarkers associated with the efficacy of first-line nivolumab (nivo) plus ipilimumab (ipi) in patients (pts) with stage IV or recurrent NSCLC. Pneumologie, 73 (S 01 S 01). https://doi.org/10.1055/s-0039-1678250
Mit CareLit weiterarbeiten